Details of the Drug

General Information of Drug (ID: DMVRLT7)

Drug Name
Fludarabine
Synonyms
FaraA; Fludarabina; Fludarabinum; Fluradosa; Fludarabina [Spanish]; Fludarabine [INN]; Fludarabinum [Latin]; SQ Fludarabine; Fludara, Fludarabine; Fludarabine (INN); Fluradosa (TN); F-Ara-A; (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-F-ara-A; 2-Fluoro Ara-A; 2-Fluoro-9-beta-D-arabinofuranosyladenine; 9-beta-D-Arabinofuranosyl-2-fluoroadenine; 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-(9CI)
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [1]
Cutaneous melanoma 2C30 Approved [1]
Haematological malignancy 2B33.Y Approved [2]
Hematologic disease 3C0Z Approved [1]
Hepatosplenic T-cell lymphoma N.A. Approved [1]
Immunodeficiency 4A00-4A85 Approved [1]
Large granular lymphocytic leukemia 2A90.1 Approved [1]
Lung cancer 2C25.0 Approved [1]
MALT lymphoma N.A. Approved [1]
Multiple sclerosis 8A40 Approved [1]
Myeloproliferative neoplasm 2A20 Approved [1]
Nodal marginal zone lymphoma 2A85.0 Approved [1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [1]
Recurrent adult burkitt lymphoma 2A85.6 Approved [1]
Small intestine lymphoma N.A. Approved [1]
Splenic marginal zone lymphoma N.A. Approved [1]
Systemic lupus erythematosus 4A40.0 Approved [1]
Systemic sclerosis 4A42 Approved [1]
Testicular lymphoma N.A. Approved [1]
Classic Hodgkin lymphoma N.A. Investigative [1]
Colon cancer 2B90.Z Investigative [1]
Gastric cancer 2B72 Investigative [1]
Neuroblastoma 2D11.2 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01BB05: Fludarabine
L01BB: Purine analogues
L01B: ANTIMETABOLITES
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 285.23
Logarithm of the Partition Coefficient (xlogp) -0.6
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 55% []
Half-life
The concentration or amount of drug in body reduced by one-half in 20 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.6598 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 3.53 mg/mL [3]
Chemical Identifiers
Formula
C10H12FN5O4
IUPAC Name
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
Canonical SMILES
C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N
InChI
InChI=1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6+,9-/m1/s1
InChIKey
HBUBKKRHXORPQB-FJFJXFQQSA-N
Cross-matching ID
PubChem CID
657237
ChEBI ID
CHEBI:94701
CAS Number
21679-14-1
UNII
P2K93U8740
DrugBank ID
DB01073
TTD ID
D0F2XQ
VARIDT ID
DR00434
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adenosine deaminase (ADA) TTLP57V ADA_HUMAN Inhibitor [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Gene/Protein Processing [7]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Gene/Protein Processing [8]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [9]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Gene/Protein Processing [9]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Gene/Protein Processing [10]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Gene/Protein Processing [11]
DNA cytosine-5)-methyltransferase 1 (DNMT1) OTM2DGTK DNMT1_HUMAN Gene/Protein Processing [12]
Dual specificity mitogen-activated protein kinase kinase 1 (MAP2K1) OT4Y9NQI MP2K1_HUMAN Gene/Protein Processing [13]
Dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2) OTUE7Z91 MP2K2_HUMAN Gene/Protein Processing [13]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Gene/Protein Processing [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC2 6.6707 8.6473 3.6659 0.6401
EW-7 GDSC2 2.0321 4.1187 1.8754 23.7948
NOS-1 [Human HNSCC] GDSC2 2.1992 6.2431 1.2987 26.1082
EW-3 GDSC2 2.6819 9.9295 0.0566 29.6329
SK-ES-1 GDSC2 3.6496 5.2325 3.2315 9.1448
CADO-ES1 GDSC2 3.9462 5.2459 3.5188 6.2939
EW-24 GDSC2 4.393 7.1223 2.9806 8.2846
SK-PN-DW GDSC2 4.3966 6.6422 3.2234 6.7404
EW-1 GDSC2 4.665 7.2439 3.1361 6.5658
EW-13 GDSC2 4.7924 6.8307 3.4347 4.388
A-673 GDSC2 4.811 7.603 3.069 6.6164
ES7 GDSC2 4.8114 10.6303 1.5658 15.5702
EW-22 GDSC2 4.8256 7.9181 2.9244 7.4791
SaOS-2 GDSC2 4.9433 9.0961 2.4309 10.2137
EW-11 GDSC2 5.0235 9.4397 2.3216 10.6664
CAL-72 GDSC2 5.0355 8.3696 2.8576 7.3782
NY GDSC2 5.2614 13.4095 0.5354 19.4626
EW-16 GDSC2 5.3578 9.2457 2.6608 7.8251
CAL-78 GDSC2 5.3735 7.345 3.5708 2.4295
G-292 clone A141B1 GDSC2 5.4295 7.8607 3.3683 3.4749
U2OS GDSC2 5.4626 8.8693 2.9142 6.079
ES4 GDSC2 5.6731 8.6124 3.1709 4.1665
ES5 GDSC2 5.7102 9.5832 2.7389 6.6042
ES8 GDSC2 5.7118 9.908 2.5851 7.5017
MHH-ES-1 GDSC2 5.8432 7.4835 3.7573 0.9179
H-EMC-SS GDSC2 5.9913 8.7314 3.3039 2.913
CHSA8926 GDSC2 6.1205 8.341 3.5396 1.5808
ES6 GDSC2 6.1899 9.7886 2.9438 4.5468
MG-63 GDSC2 6.4847 8.0757 3.802 0.3577
HOS GDSC2 6.4985 7.9771 3.8424 0.2608
HuO9 GDSC2 6.5952 8.8612 3.5517 1.0831
TC-71 GDSC2 6.7558 8.4056 3.7869 0.2891
EW-18 GDSC2 6.9282 8.941 3.6607 0.5193
HuO-3N1 GDSC2 7.1825 9.5294 3.5455 0.7121
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE-12 GDSC2 -0.1587 4.3287 -0.5697 45.7775
ESO-26 GDSC2 3.9159 5.4347 3.3992 7.1404
OACM5.1 C GDSC2 4.5565 6.5105 3.4165 5.0858
OACP4 C GDSC2 4.8016 7.4491 3.1379 6.2102
FLO-1 GDSC2 4.9037 8.7617 2.5663 9.4914
KYSE-220 GDSC2 5.3652 9.6136 2.4871 8.8471
ESO-51 GDSC2 6.1219 8.1446 3.6209 1.2229
KYSE-50 GDSC2 6.7817 8.8591 3.6321 0.6787
KYAE-1 GDSC2 6.8394 8.3005 3.8535 0.1497
SK-GT-4 GDSC2 7.7136 19.2089 -0.5196 18.1483
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC2 6.8759 8.9348 3.6422 0.5967
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SK-N-BE(2)-M17 GDSC2 2.4337 7.596 0.9315 26.925
CHP-212 GDSC2 2.84 5.1742 2.4123 17.2282
SiMa GDSC2 3.9249 7.7971 2.2433 14.2851
SK-N-DZ GDSC2 4.8403 7.4914 3.1457 6.0668
NH-12 GDSC2 4.8951 8.5854 2.647 9.0191
KP-N-YN GDSC2 4.907 13.2987 0.3113 21.396
NB69 GDSC2 5.1768 9.1618 2.5722 8.7803
GI-ME-N GDSC2 5.3199 9.3984 2.5597 8.5184
IMR-5 GDSC2 5.7056 10.1958 2.4428 8.3463
SJNB-7 GDSC2 5.7691 7.9839 3.5099 2.1591
Kelly GDSC2 5.78 8.4629 3.3033 3.2418
SJNB-13 GDSC2 5.849 8.2294 3.4462 2.3755
TGW GDSC2 6.0616 10.9389 2.3268 8.2655
CHP-134 GDSC2 6.0987 8.3206 3.5373 1.6155
SJNB-14 GDSC2 6.3462 7.9335 3.7996 0.4272
NB(TU)1 GDSC2 6.3892 8.0884 3.7596 0.5181
GOTO GDSC2 6.7474 8.8486 3.622 0.731
SK-N-AS GDSC2 6.7537 14.6391 1.0223 13.6692
SJNB-10 GDSC2 6.8513 8.4027 3.8228 0.1944
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC2 5.4482 7.6854 3.4603 2.92
Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MDA-MB-231 GDSC2 -1.0364 0.4553 -1.037 53.7667
BT-549 GDSC2 0.0514 4.2568 -0.3211 43.8589
BT-20 GDSC2 0.2496 3.0825 0.1444 41.2714
EFM-192A GDSC2 1.9421 4.7677 1.5906 25.7302
HCC1954 GDSC2 2.0589 5.5768 1.424 26.0786
CAL-51 GDSC2 4.0004 5.8049 3.298 7.4826
HCC1806 GDSC2 4.1954 5.5028 3.623 4.807
MRK-nu-1 GDSC2 4.3442 5.561 3.7209 3.7414
DU4475 GDSC2 4.6576 6.0817 3.7037 3.0399
MDA-MB-157 GDSC2 4.6834 7.9182 2.8154 8.5246
MDA-MB-361 GDSC2 4.6899 9.3769 2.0942 12.9027
CAL-85-1 GDSC2 4.7537 7.7871 2.9347 7.5978
HCC38 GDSC2 4.804 7.8159 2.9586 7.3208
CAL-120 GDSC2 4.9446 8.36 2.7954 7.9815
HCC1500 GDSC2 5.0553 9.831 2.1521 11.5894
AU565 GDSC2 5.243 7.3411 3.4935 3.0941
HCC1428 GDSC2 5.4604 7.3788 3.6056 2.104
T-47D GDSC2 5.5345 9.4799 2.6702 7.3781
MCF-7 GDSC2 5.5678 7.6929 3.5266 2.3641
Hs 578T GDSC2 5.5863 8.7231 3.0647 4.9414
BT-474 GDSC2 5.6754 7.4152 3.7045 1.3217
MDA-MB-415 GDSC2 5.6758 7.9076 3.492 2.3858
HCC1143 GDSC2 5.8339 8.6744 3.2393 3.5065
CAMA-1 GDSC2 5.8699 10.3439 2.4828 7.767
MFM-223 GDSC2 5.878 7.6806 3.6939 1.151
COLO 824 GDSC2 5.9156 8.7883 3.2355 3.3953
MDA-MB-453 GDSC2 5.9646 9.4445 2.9657 4.8116
HCC1569 GDSC2 6.0512 8.982 3.2264 3.234
HCC1419 GDSC2 6.1323 7.789 3.7659 0.6564
JIMT-1 GDSC2 6.198 7.6605 3.841 0.3872
HCC1937 GDSC2 6.3926 8.4959 3.6049 1.0454
ZR-75-30 GDSC2 6.3973 8.2736 3.6932 0.7229
HCC70 GDSC2 6.4347 8.6656 3.5567 1.1984
HCC1187 GDSC2 6.533 8.2271 3.7659 0.4277
HCC2157 GDSC2 6.5562 8.0591 3.8349 0.2569
Evsa-T GDSC2 6.7172 8.3058 3.8077 0.2595
OCUB-M GDSC2 6.7354 8.5057 3.7435 0.3946
EFM-19 GDSC2 6.8512 8.7105 3.7143 0.4171
HDQ-P1 GDSC2 6.8957 8.5942 3.7724 0.273
MDA-MB-436 GDSC2 6.904 8.9432 3.6503 0.5594
MDA-MB-330 GDSC2 7.1284 9.4287 3.561 0.6961
MDA-MB-468 GDSC2 7.2296 8.9615 3.7658 0.1953
⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-118MG GDSC2 -0.5089 5.1817 -1.2077 48.8662
LN-18 GDSC2 0.5762 4.4616 0.1952 39.0842
D283 Med GDSC2 3.8863 4.935 3.605 5.988
DBTRG-05MG GDSC2 4.9894 8.036 2.9875 6.6881
CAS-1 GDSC2 5.0102 7.188 3.414 4.0287
YH-13 GDSC2 5.0217 6.96 3.5306 3.3037
DK-MG GDSC2 5.0231 7.8096 3.1223 5.7807
42-MG-BA GDSC2 5.3812 9.8448 2.3858 9.411
D-263MG GDSC2 5.3864 10.0216 2.3032 9.8862
H4 GDSC2 5.4306 13.1681 0.7854 17.8776
AM-38 GDSC2 5.4695 7.6143 3.5053 2.6345
Daoy GDSC2 5.5698 8.2704 3.2654 3.8119
GB-1 GDSC2 5.6228 7.3664 3.6983 1.413
KINGS-1 GDSC2 5.7082 10.687 2.2076 9.7023
D-392MG GDSC2 5.8532 9.0243 3.0912 4.2997
U-251MG GDSC2 5.9536 8.1752 3.5251 1.8424
SF539 GDSC2 6.1901 7.8962 3.7495 0.6728
A-172 GDSC2 6.2433 8.2369 3.64 1.0344
SK-MG-1 GDSC2 6.3622 8.3383 3.6531 0.8886
SW1088 GDSC2 6.4028 8.8804 3.4546 1.6595
Becker GDSC2 6.4568 8.2287 3.7349 0.5538
8-MG-BA GDSC2 6.4658 9.157 3.3709 1.968
GI-1 GDSC2 6.4858 8.0974 3.7946 0.3754
LN-405 GDSC2 6.6019 8.0576 3.8522 0.2095
U-87MG ATCC GDSC2 6.6136 8.1089 3.8386 0.2315
M059J GDSC2 6.6913 8.3802 3.7717 0.3458
GaMG GDSC2 6.7479 12.8166 1.8861 9.3202
KS-1 [Human Krukenberg tumour] GDSC2 6.8326 11.6215 2.4915 5.9348
PFSK-1 GDSC2 6.8974 8.7963 3.7012 0.4297
ONS-76 GDSC2 6.9686 8.5117 3.8271 0.1608
T98G GDSC2 7.0522 8.9856 3.6925 0.3879
LN-229 GDSC2 7.1292 8.7325 3.8084 0.1546
KALS-1 GDSC2 7.1355 9.1674 3.6591 0.4325
SF268 GDSC2 7.2939 9.2183 3.7003 0.2904
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TGBC24TKB GDSC2 5.7099 12.6409 1.2549 14.883
ETK-1 GDSC2 6.84 9.2211 3.519 1.0157
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RL95-2 GDSC2 4.8397 6.7593 3.5031 3.8586
MFE-319 GDSC2 5.0298 7.2561 3.3946 4.1038
ESS-1 GDSC2 6.1315 7.6668 3.8119 0.5074
EN GDSC2 6.3221 7.8511 3.8202 0.3835
MFE-296 GDSC2 6.5881 8.1311 3.8213 0.2743
KLE GDSC2 6.8508 9.1207 3.5622 0.8596
AN3-CA GDSC2 7.1416 9.0001 3.7207 0.2974
MFE-280 GDSC2 7.4942 9.9435 3.5173 0.6315
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 128 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
WSU-NHL GDSC2 -4.4061 -2.9231 -4.4061 86.5813
LAMA-84 GDSC2 -3.7017 -1.4063 -3.7026 79.0033
JURL-MK1 GDSC2 -2.4356 -0.1938 -2.4383 67.394
SU-DHL-5 GDSC2 -1.62 -0.9285 -1.62 59.6275
NALM-6 GDSC2 -0.7477 1.0755 -0.7513 50.8695
SUP-B15 GDSC2 -0.6695 1.2863 -0.676 50.0886
RS4;11 GDSC2 -0.1191 2.6189 -0.1877 44.7674
Karpas-231 GDSC2 0.0262 1.877 0.016 43.1491
RC-K8 GDSC2 0.1504 1.7727 0.1452 41.8848
P30/OHK GDSC2 0.3503 2.0639 0.3408 39.9002
697 GDSC2 0.3933 2.2212 0.3787 39.4918
LC4-1 GDSC2 0.4227 2.0741 0.4143 39.1689
MLMA GDSC2 0.5035 2.8872 0.4411 38.5986
DND-41 GDSC2 0.5269 2.2527 0.5145 38.1427
VAL GDSC2 0.5288 2.2957 0.5146 38.1322
P32/ISH GDSC2 0.5412 1.4162 0.5412 37.94
BALL-1 GDSC2 0.5882 2.2623 0.5769 37.5229
CTV-1 GDSC2 0.6047 1.7066 0.6041 37.3056
HAL-01 GDSC2 0.6226 2.7405 0.5819 37.315
Jurkat GDSC2 0.6313 1.6927 0.6308 37.0382
MHH-CALL-2 GDSC2 0.745 2.2477 0.7378 35.9304
Reh GDSC2 0.7502 2.4282 0.7361 35.9117
EM-2 GDSC2 0.7634 2.3668 0.7524 35.7646
EoL-1 GDSC2 0.7933 2.8903 0.7471 35.6333
ALL-PO GDSC2 0.8022 2.9235 0.7531 35.558
Ku812 GDSC2 0.897 3.8481 0.7021 35.2799
KOPN-8 GDSC2 0.9245 2.5902 0.9075 34.1782
CML-T1 GDSC2 0.9788 3.0013 0.9313 33.7832
OCI-AML-5 GDSC2 0.9927 2.6016 0.9774 33.4854
SUP-T1 GDSC2 1.047 3.7607 0.884 33.6546
MOLT-16 GDSC2 1.0569 2.5942 1.0439 32.8302
MOLT-13 GDSC2 1.204 3.4605 1.1098 31.7587
OCI-AML-2 GDSC2 1.232 2.5569 1.2248 31.044
HEL GDSC2 1.3936 3.3193 1.3337 29.689
SK-MM-2 GDSC2 1.3992 2.9635 1.3762 29.4458
ALL-SIL GDSC2 1.5747 3.7941 1.4497 28.2075
WIL2 NS GDSC2 1.6549 2.6898 1.6517 26.7799
KY821 GDSC2 1.6797 2.9723 1.6667 26.5807
TK [Human B-cell lymphoma] GDSC2 1.7682 4.8029 1.3902 27.5883
KE-37 GDSC2 1.9927 3.7544 1.9094 23.802
CCRF-CEM GDSC2 2.0787 3.8765 1.9795 23.0229
GA-10 GDSC2 2.0837 5.3124 1.5519 25.2928
MOLM-13 GDSC2 2.0912 3.3901 2.0647 22.5201
SU-DHL-8 GDSC2 2.3183 3.5597 2.2867 20.2675
Raji GDSC2 2.3229 3.5233 2.2955 20.1999
HL-60 GDSC2 2.3461 3.3764 2.3324 19.8971
OCI-AML-3 GDSC2 2.3688 4.7474 2.0608 21.2481
ME1 GDSC2 2.3837 6.5095 1.3736 24.9315
PF-382 GDSC2 2.4226 5.0813 2.0015 21.3401
A4/Fukuda GDSC2 2.4535 4.8352 2.1228 20.5288
Hs 445 GDSC2 2.4737 4.5527 2.2374 19.8049
TUR GDSC2 2.4853 4.3321 2.3147 19.3295
ATN-1 GDSC2 2.508 4.0482 2.4098 18.7126
P12-Ichikawa GDSC2 2.5896 4.1608 2.4728 17.9939
HDLM-2 GDSC2 2.6371 5.3164 2.1408 19.6355
MEG-01 GDSC2 2.6579 8.3466 0.7972 26.6453
NOMO-1 GDSC2 2.7257 4.5538 2.5115 17.1613
Namalwa GDSC2 2.7422 4.7886 2.4512 17.4249
ST486 GDSC2 2.7515 6.1837 1.8937 20.5745
KG-1 GDSC2 3.1058 5.2456 2.6642 14.6679
H9 GDSC2 3.1141 5.5139 2.5593 15.2507
Kasumi-1 GDSC2 3.1739 5.7812 2.503 15.3496
HC-1 GDSC2 3.2019 4.4807 3.0529 12.0351
L-428 GDSC2 3.2696 5.7352 2.6207 14.2767
L-1236 GDSC2 3.4207 7.152 2.1001 16.8454
Karpas-1106P GDSC2 3.4923 5.8842 2.7746 12.5067
DoHH2 GDSC2 3.6831 4.6138 3.5279 7.2607
Granta-519 GDSC2 3.6948 6.059 2.888 11.0813
SKM-1 GDSC2 3.9841 4.8018 3.764 4.6554
ML-2 GDSC2 4.0205 5.215 3.6047 5.5008
JSC-1 GDSC2 4.0258 5.1446 3.6437 5.2407
DG-75 GDSC2 4.0745 6.88 2.8313 10.1764
JVM-3 GDSC2 4.0837 5.3712 3.5875 5.3922
BL-41 GDSC2 4.0968 5.1058 3.7296 4.4606
MN-60 GDSC2 4.1159 6.9118 2.8516 9.9205
GDM-1 GDSC2 4.1738 6.0767 3.3182 6.7989
MM1.S GDSC2 4.1779 5.3952 3.661 4.623
MHH-PREB-1 GDSC2 4.2495 5.5002 3.6714 4.334
CA46 GDSC2 4.269 8.2029 2.3371 12.6507
KCL-22 GDSC2 4.2962 5.7742 3.5742 4.8095
GR-ST GDSC2 4.2965 7.813 2.5552 11.2278
DB GDSC2 4.3748 5.8672 3.5929 4.4642
Karpas-45 GDSC2 4.3846 5.883 3.593 4.4365
Farage GDSC2 4.3892 7.1819 2.9477 8.5026
MOLT-4 GDSC2 4.494 7.075 3.086 7.337
CESS GDSC2 4.5041 5.9078 3.6752 3.5948
SCC-3 GDSC2 4.517 5.6399 3.8176 2.6689
U-698-M GDSC2 4.5196 8.6468 2.3219 12.0158
BE-13 GDSC2 4.5288 6.3097 3.4948 4.6657
JJN-3 GDSC2 4.6196 7.0991 3.1729 6.4531
MOLP-8 GDSC2 4.6565 6.1283 3.6801 3.1882
OPM-2 GDSC2 4.6858 6.3193 3.6079 3.5666
SU-DHL-10 GDSC2 4.7513 7.5353 3.0576 6.8369
AMO1 GDSC2 4.7791 6.7421 3.4685 4.2108
SU-DHL-6 GDSC2 4.8496 6.5894 3.5921 3.2931
OCI-M1 GDSC2 4.8669 6.297 3.7433 2.3492
Loucy GDSC2 4.8936 7.5655 3.1484 5.9221
Daudi GDSC2 4.9862 6.6354 3.6608 2.6026
Karpas-422 GDSC2 5.0015 7.376 3.3174 4.6342
Karpas-299 GDSC2 5.0791 7.259 3.4264 3.8093
KMS-12-BM GDSC2 5.1863 8.0165 3.1359 5.334
IM-9 GDSC2 5.2434 7.1307 3.5909 2.5361
L-540 GDSC2 5.2557 7.5739 3.3927 3.6579
NCI-H929 GDSC2 5.269 11.6586 1.4098 15.1843
U266B1 GDSC2 5.4669 7.4334 3.585 2.2048
JVM-2 GDSC2 5.5307 7.6712 3.5151 2.4827
Ramos.2G6.4C10 GDSC2 5.6561 7.3425 3.7253 1.2475
DEL GDSC2 5.6647 6.8926 3.9099 0.4856
EB2 GDSC2 5.6651 7.6268 3.6091 1.7972
SR GDSC2 5.7586 7.2167 3.8249 0.7235
ARH-77 GDSC2 5.7679 7.9601 3.5197 2.111
KM-H2 GDSC2 5.8188 9.159 3.0079 4.834
KMOE-2 GDSC2 5.8211 8.0576 3.5059 2.1084
A3/Kawakami GDSC2 5.8329 6.9225 3.9666 0.2309
SUP-M2 GDSC2 5.9037 6.9998 3.9658 0.2058
Karpas-620 GDSC2 5.9536 7.4092 3.8351 0.5436
L-363 GDSC2 6.0697 7.5301 3.8377 0.4644
LP-1 GDSC2 6.2304 7.7681 3.8143 0.445
RPMI-8226 GDSC2 6.2904 8.0739 3.7242 0.6905
RPMI-8866 GDSC2 6.4632 8.1852 3.7536 0.4959
BC-1 GDSC2 6.5373 8.4319 3.6918 0.6386
K-562 GDSC2 6.5502 8.0757 3.8268 0.2757
Jiyoye GDSC2 6.6043 8.2242 3.7944 0.3273
RPMI-6666 GDSC2 6.6303 8.4863 3.7094 0.5341
VL51 GDSC2 6.7206 8.6279 3.6933 0.5329
EJM GDSC2 6.8071 8.4633 3.7857 0.2747
SUP-HD1 GDSC2 6.8623 8.9523 3.6302 0.6387
HH [Human lymphoma] GDSC2 7.0395 8.9271 3.7085 0.3571
⏷ Show the Full List of 128 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CAL-54 GDSC2 -4.6946 3.2128 -5.2389 72.73
769-P GDSC2 4.7347 8.3555 2.6379 9.4908
SN12C GDSC2 4.7376 6.9796 3.3216 5.2223
RCC10RGB GDSC2 5.14 6.8539 3.6554 2.3511
BFTC-909 GDSC2 5.3584 10.0638 2.2623 10.1926
A-704 GDSC2 5.4784 8.734 2.9893 5.5997
786-O GDSC2 5.5682 7.7752 3.49 2.5604
OS-RC-2 GDSC2 5.5828 7.4019 3.6624 1.639
A-498 GDSC2 5.5923 7.7769 3.5031 2.4525
ACHN GDSC2 5.6959 10.1467 2.4598 8.2679
SW13 GDSC2 5.845 7.8342 3.6139 1.5495
RXF 393L GDSC2 5.8861 9.3677 2.9529 5.0255
KTCTL-195 GDSC2 6.2416 8.7621 3.4239 1.9789
TK-10 GDSC2 6.3665 8.9812 3.3949 1.97
KMRC-20 GDSC2 6.4643 8.2437 3.7323 0.5573
VMRC-RCZ GDSC2 6.5399 8.1608 3.7926 0.3573
NCC010 GDSC2 6.5955 9.1736 3.427 1.5841
HA7-RCC GDSC2 6.6539 8.9682 3.5358 1.096
LB996-RCC GDSC2 6.7158 9.0771 3.5206 1.1039
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW626 GDSC2 -0.2324 3.6621 -0.485 46.1948
SK-CO-1 GDSC2 3.5442 5.1058 3.1799 9.8642
GP5d GDSC2 4.1115 5.3155 3.6404 4.9683
LS513 GDSC2 4.1865 5.5227 3.6052 4.9477
SNU-175 GDSC2 4.4247 7.5986 2.7684 9.5278
MDST8 GDSC2 4.4505 6.2199 3.4779 4.9816
LS411N GDSC2 4.5383 7.0305 3.1434 6.8544
HCC2998 GDSC2 4.5618 9.277 2.0413 13.5726
LS180 GDSC2 4.6761 6.4315 3.5458 3.9753
LoVo GDSC2 4.7184 7.1057 3.245 5.748
SW48 GDSC2 4.7571 6.9111 3.3697 4.8754
COLO205 GDSC2 4.9095 6.9293 3.4695 3.9092
CW-2 GDSC2 4.9921 6.9841 3.4994 3.5513
HCT 15 GDSC2 5.088 7.1243 3.4962 3.3752
CL-11 GDSC2 5.125 7.0395 3.5598 2.929
HT115 GDSC2 5.2068 7.0731 3.5952 2.5759
HT-29 GDSC2 5.2885 7.6072 3.398 3.5638
SNU-81 GDSC2 5.3029 8.4946 2.9857 5.99
SW1463 GDSC2 5.3083 9.1275 2.6833 7.8023
C2BBe1 GDSC2 5.327 10.399 2.0749 11.3587
RKO GDSC2 5.3593 9.4812 2.5474 8.5008
SW1116 GDSC2 5.3867 7.3434 3.5792 2.3618
SNU-C5 GDSC2 5.4824 7.933 3.3675 3.3853
CCK-81 GDSC2 5.8134 8.418 3.3428 2.9744
HCT 116 GDSC2 5.8409 7.695 3.67 1.2952
SNU-407 GDSC2 5.9012 8.5112 3.351 2.7977
HT-55 GDSC2 6.054 7.3409 3.901 0.2977
KM12 GDSC2 6.1192 8.282 3.5634 1.4751
RCM-1 [Human ESC] GDSC2 6.1257 7.3257 3.9334 0.198
T84 GDSC2 6.1576 8.7858 3.3704 2.342
COLO 320HSR GDSC2 6.167 7.9189 3.7308 0.7542
SW1417 GDSC2 6.2308 9.3901 3.1463 3.3896
SNU-1040 GDSC2 6.2802 7.8095 3.8189 0.407
SNU-C1 GDSC2 6.3274 8.1892 3.6958 0.7622
SW948 GDSC2 6.3915 7.7634 3.8779 0.2237
LS1034 GDSC2 6.4571 7.8787 3.8617 0.2351
SW837 GDSC2 6.5022 8.1341 3.7877 0.3856
SW620 GDSC2 6.6131 8.549 3.6791 0.6331
NCI-H716 GDSC2 6.616 8.7769 3.5936 0.9141
LS123 GDSC2 6.7033 9.2045 3.4647 1.3293
CaR-1 GDSC2 6.7668 8.6675 3.6971 0.4996
NCI-H747 GDSC2 6.8745 8.9854 3.6229 0.6536
COLO 678 GDSC2 7.0674 9.2564 3.6002 0.616
SNU-61 GDSC2 7.1071 8.8229 3.7697 0.2182
SNU-C2B GDSC2 7.4424 11.1372 3.0298 2.4443
DiFi GDSC2 7.9868 9.9727 3.6876 0.1559
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC2 6.395 8.1289 3.7469 0.5527
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-398 GDSC2 0.0403 1.7254 0.0346 42.9904
JHH-6 GDSC2 4.6887 6.5194 3.5119 4.156
JHH-2 GDSC2 4.8543 6.8071 3.4901 3.9054
SK-HEP-1 GDSC2 4.86 7.1236 3.3403 4.8141
Hep-G2/C3A GDSC2 4.8927 6.3469 3.7364 2.339
Hep 3B2.1-7 GDSC2 5.1562 7.3793 3.4201 3.6911
SNU-423 GDSC2 5.3661 16.0858 -0.7141 24.1009
SNU-387 GDSC2 5.7176 7.813 3.5565 1.9923
HuH-1 GDSC2 5.7712 7.9043 3.5456 1.9748
HLE GDSC2 5.9949 9.548 2.9366 4.9225
JHH-1 GDSC2 6.0871 7.3091 3.9249 0.2287
JHH-4 GDSC2 6.7133 11.6151 2.4231 6.5034
JHH-7 GDSC2 6.8233 9.6239 3.3519 1.6809
Huh-7 GDSC2 7.181 8.6408 3.8569 0.0896
SNU-449 GDSC2 7.1816 8.8856 3.7748 0.1924
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 129 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H2122 GDSC2 -2.3956 -1.1556 -2.3956 67.3928
NCI-H446 GDSC2 -0.8776 2.423 -0.969 52.0248
NCI-H1755 GDSC2 -0.8756 5.5892 -1.7408 51.4874
HCC78 GDSC2 3.5846 5.2014 3.1794 9.7086
NCI-H1944 GDSC2 3.8124 5.2799 3.3724 7.6779
NCI-H1048 GDSC2 3.8554 6.9823 2.5854 12.413
COLO 668 GDSC2 3.8565 6.2589 2.9426 10.1857
NCI-H322M GDSC2 3.8957 11.0313 0.6057 23.1148
IST-SL2 GDSC2 4.065 5.4214 3.5457 5.7167
Lu-99A GDSC2 4.0792 5.8974 3.3237 7.0633
NCI-H526 GDSC2 4.1332 5.2538 3.6907 4.5811
A-427 GDSC2 4.2703 7.8264 2.5265 11.4832
NCI-H2023 GDSC2 4.4957 6.023 3.6115 4.0173
NCI-H2228 GDSC2 4.5133 9.1696 2.0557 13.6263
NCI-H1155 GDSC2 4.5375 7.1317 3.0924 7.1783
HOP-62 GDSC2 4.5876 6.4826 3.4542 4.7687
SK-MES-1 GDSC2 4.5902 6.5948 3.4006 5.0986
COR-L311 GDSC2 4.6283 6.1188 3.6643 3.3533
LCLC-103H GDSC2 4.6917 6.5249 3.5114 4.1516
LXF 289 GDSC2 4.6956 9.2155 2.1792 12.3835
NCI-H82 GDSC2 4.7085 6.4475 3.5615 3.8002
HOP-92 GDSC2 4.7149 9.7396 1.9332 13.7734
DMS 273 GDSC2 4.7639 6.5977 3.528 3.878
HCC44 GDSC2 4.7747 7.0285 3.325 5.1111
NCI-H2722 GDSC2 4.8393 9.1694 2.3147 11.1855
NCI-H2170 GDSC2 4.8649 6.8636 3.4702 4.0039
NCI-H1623 GDSC2 5.0071 9.2681 2.394 10.2737
NCI-H2461 GDSC2 5.0338 7.6965 3.1848 5.3729
NCI-H1581 GDSC2 5.0355 7.2431 3.4047 4.0309
HCC366 GDSC2 5.0959 7.2157 3.4581 3.5859
NCI-H1975 GDSC2 5.1116 8.0622 3.062 5.9484
SK-LU-1 GDSC2 5.1288 7.2944 3.4423 3.6136
NCI-H513 GDSC2 5.1373 8.5211 2.857 7.1423
NCI-H1355 GDSC2 5.1682 9.3402 2.4784 9.3667
NCI-H596 GDSC2 5.179 10.0985 2.1131 11.5046
NCI-H358 GDSC2 5.1995 7.9558 3.1741 5.075
DMS 79 GDSC2 5.1997 7.6151 3.3368 4.0986
Lu-139 GDSC2 5.1999 8.4862 2.9184 6.6249
NCI-H1666 GDSC2 5.2206 8.5722 2.8911 6.7437
RERF-LC-KJ GDSC2 5.2218 8.5045 2.9248 6.5362
NCI-H2369 GDSC2 5.2342 7.9701 3.1907 4.9022
NCI-H1781 GDSC2 5.2427 7.6451 3.3508 3.9299
NCI-H1563 GDSC2 5.2702 7.7302 3.3285 4.0075
NCI-H211 GDSC2 5.2908 8.5638 2.944 6.2676
EMC-BAC-2 GDSC2 5.299 9.1677 2.6572 7.9807
LCLC-97TM1 GDSC2 5.3142 8.1356 3.1651 4.8893
Lu-165 GDSC2 5.3188 9.1273 2.6908 7.7331
NCI-H226 GDSC2 5.3246 6.6226 3.8607 0.9969
SHP-77 GDSC2 5.3369 7.1913 3.6189 2.2244
NCI-H2373 GDSC2 5.3489 7.5562 3.4594 3.0978
NCI-H650 GDSC2 5.3501 9.19 2.6824 7.7125
HCC827 GDSC2 5.3582 9.3835 2.5941 8.224
NCI-H1435 GDSC2 5.4122 8.5491 3.0334 5.4737
NCI-H1915 GDSC2 5.4308 7.9283 3.3378 3.6483
SBC-3 GDSC2 5.5254 7.9521 3.3847 3.213
SBC-5 GDSC2 5.543 6.6222 3.9615 0.3941
COR-L23 GDSC2 5.5559 12.0889 1.4127 14.4458
NCI-H2869 GDSC2 5.6159 9.6811 2.6289 7.4474
PC-14 GDSC2 5.6675 7.701 3.5782 1.95
HCC15 GDSC2 5.6892 12.4952 1.3112 14.6455
CPC-N GDSC2 5.702 7.8193 3.5453 2.0706
NCI-H345 GDSC2 5.7162 6.6241 4.0285 0.1396
NCI-H3122 GDSC2 5.726 9.1009 2.9767 5.1864
NCI-H727 GDSC2 5.7345 8.6911 3.1723 4.0494
NCI-H2810 GDSC2 5.7747 10.8488 2.1755 9.7376
NCI-H2135 GDSC2 5.7753 7.684 3.6419 1.4994
NCI-H23 GDSC2 5.7909 8.2375 3.4104 2.6469
DMS 114 GDSC2 5.8073 8.3474 3.3708 2.8333
NCI-H2085 GDSC2 5.8487 9.2811 2.9698 4.9974
Lu-65 GDSC2 5.8873 7.6978 3.6913 1.1528
NCI-H2818 GDSC2 5.9197 8.8797 3.1967 3.6008
LC-1/sq GDSC2 5.9291 14.559 0.4732 18.0574
NCI-H3255 GDSC2 5.9297 11.7097 1.867 11.1225
NCI-H520 GDSC2 5.9551 11.5144 1.979 10.4466
NCI-H841 GDSC2 5.9574 8.0767 3.5687 1.6307
Calu-3 GDSC2 5.9732 9.425 2.9799 4.7164
ABC-1 GDSC2 5.9768 8.1593 3.5437 1.7253
NCI-H1299 GDSC2 5.9941 8.3482 3.4724 2.0489
Calu-6 GDSC2 5.9994 8.2533 3.5155 1.8327
NCI-H720 GDSC2 6.0139 7.2357 3.9234 0.26
NCI-H810 GDSC2 6.0147 7.6045 3.7864 0.668
NCI-H2141 GDSC2 6.0255 7.4803 3.8382 0.4885
Ms-1 GDSC2 6.0543 7.8811 3.6954 0.9789
EPLC-272H GDSC2 6.0642 14.8545 0.4277 17.9344
NCI-H1694 GDSC2 6.0753 7.7378 3.7611 0.7135
NCI-H1793 GDSC2 6.1433 7.8296 3.755 0.6861
VMRC-LCD GDSC2 6.1648 7.8501 3.7564 0.6666
KNS-62 GDSC2 6.176 7.7684 3.7921 0.5424
SW1271 GDSC2 6.2077 8.0767 3.6872 0.8826
NCI-H1651 GDSC2 6.2137 9.182 3.2285 2.985
NCI-H524 GDSC2 6.2838 7.9754 3.7588 0.5817
NCI-H1092 GDSC2 6.3 8.0112 3.752 0.5934
NCI-H2804 GDSC2 6.3042 9.5826 3.1022 3.513
NCI-H209 GDSC2 6.3149 8.3269 3.6367 0.9874
NCI-H2227 GDSC2 6.3951 10.3694 2.8014 4.9864
DMS 53 GDSC2 6.4031 8.4747 3.618 0.9872
Lu-135 GDSC2 6.4254 8.1005 3.7697 0.4699
NCI-H1993 GDSC2 6.4259 8.3687 3.669 0.7857
NCI-H196 GDSC2 6.4278 7.9906 3.8108 0.3602
UMC-11 GDSC2 6.4606 8.1011 3.7834 0.4154
NCI-H1792 GDSC2 6.5148 8.9796 3.4676 1.4905
NCI-H2029 GDSC2 6.5546 7.9542 3.8709 0.1892
SW1573 GDSC2 6.5702 10.8723 2.6765 5.375
IA-LM GDSC2 6.6107 8.3477 3.7524 0.4269
LOU-NH91 GDSC2 6.6227 8.4068 3.7356 0.4655
NCI-H661 GDSC2 6.6605 8.4729 3.7263 0.4723
NCI-H1869 GDSC2 6.6666 9.2174 3.4426 1.4514
NCI-H2405 GDSC2 6.6787 9.4269 3.3634 1.7745
A-549 GDSC2 6.7209 16.4426 0.1259 17.7159
NCI-H2731 GDSC2 6.734 8.6221 3.7007 0.5056
EKVX GDSC2 6.7611 9.7192 3.283 2.0431
NCI-H2795 GDSC2 6.7683 12.764 1.9239 9.0811
EBC-1 GDSC2 6.8153 8.916 3.6246 0.6821
NCI-H1693 GDSC2 6.821 8.662 3.7202 0.4155
NCI-H1876 GDSC2 6.8551 8.8602 3.6614 0.5534
LK-2 GDSC2 6.8577 15.2655 0.7921 14.5269
NCI-H250 GDSC2 6.8599 9.6321 3.3657 1.589
RERF-LC-Sq1 GDSC2 6.8966 10.2359 3.1349 2.5688
NCI-H522 GDSC2 6.9793 8.7972 3.732 0.3279
NCI-H1650 GDSC2 7.0174 8.9567 3.6896 0.4083
NCI-H2595 GDSC2 7.0316 8.9163 3.7094 0.3579
NCI-H1963 GDSC2 7.1007 8.9291 3.7305 0.291
NCI-H2803 GDSC2 7.1525 8.9199 3.7525 0.2357
NCI-H2591 GDSC2 7.1684 9.3775 3.5958 0.5779
COR-L105 GDSC2 7.1888 13.7592 1.7248 9.3306
NCI-H2087 GDSC2 7.2068 9.0816 3.7161 0.2864
HARA [Human squamous cell lung carcinoma] GDSC2 7.2533 8.9021 3.7943 0.1499
NCI-H1568 GDSC2 7.3291 19.8676 -1.1095 20.9569
NCI-H441 GDSC2 7.5952 20.1946 -1.0796 20.3222
⏷ Show the Full List of 129 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC2 5.8563 8.0225 3.5397 1.8931
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-140 GDSC2 -0.2807 3.3951 -0.4817 46.5594
TE-1 GDSC2 0.5973 3.5462 0.4396 38.063
OE33 GDSC2 3.2409 6.239 2.361 15.9426
TE-15 GDSC2 4.0997 7.1725 2.7075 10.8736
KYSE-270 GDSC2 5.2857 7.4501 3.4695 3.1542
KYSE-450 GDSC2 5.3072 17.2782 -1.3546 26.3012
KYSE-70 GDSC2 5.3912 10.0071 2.3137 9.8129
TE-5 GDSC2 5.4305 7.6288 3.4756 2.8644
KYSE-180 GDSC2 5.6249 17.004 -0.9686 24.3072
KYSE-410 GDSC2 5.8664 7.9899 3.5589 1.7868
OE19 GDSC2 5.9971 7.3069 3.891 0.3497
TE-6 GDSC2 6.4075 8.9863 3.4131 1.8402
EC-GI-10 GDSC2 6.4881 8.2008 3.7578 0.4713
TE-9 GDSC2 6.5476 7.8155 3.9159 0.1211
OE21 GDSC2 6.5921 8.5727 3.6615 0.7012
COLO 680N GDSC2 6.6418 14.4141 1.0539 13.7553
KYSE-520 GDSC2 6.7319 13.708 1.4535 11.5939
TE-4 GDSC2 6.8372 8.67 3.7236 0.4006
TE-8 GDSC2 6.9043 8.9451 3.6497 0.5609
KYSE-510 GDSC2 9.8149 26.5195 -2.6001 20.809
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OVCAR-8 GDSC2 1.9903 4.2554 1.7952 24.4172
A2780 GDSC2 4.0103 5.837 3.2913 7.4916
ES-2 GDSC2 4.3916 7.1312 2.975 8.3236
OVK18 GDSC2 4.5431 8.5914 2.3686 11.6661
TOV-21G GDSC2 4.5819 6.1005 3.6389 3.6249
TYK-nu GDSC2 4.6495 6.2539 3.6135 3.6185
TOV-112D GDSC2 4.7173 8.1493 2.7269 8.9853
OAW42 GDSC2 5.3127 6.9223 3.7251 1.6905
EFO-27 GDSC2 5.3826 10.5677 2.0328 11.4655
OVCAR-5 GDSC2 5.5399 8.7071 3.0423 5.1633
OVCAR-3 GDSC2 5.5448 7.5622 3.5717 2.1583
OV-90 GDSC2 5.5649 7.7858 3.4834 2.6016
OV56 GDSC2 5.6428 6.9733 3.8689 0.65
EFO-21 GDSC2 5.6811 9.121 2.9385 5.4947
DOV13 GDSC2 5.7061 7.8433 3.5371 2.1073
IGROV-1 GDSC2 5.8823 7.9775 3.5724 1.7023
OVISE GDSC2 5.9405 7.2591 3.8861 0.3929
SK-OV-3 GDSC2 5.9961 11.3192 2.101 9.6761
OVCAR-4 GDSC2 6.1599 9.4381 3.0846 3.8273
Kuramochi GDSC2 6.1695 9.0579 3.2587 2.8919
OVTOKO GDSC2 6.5537 15.5124 0.46 16.6714
OAW28 GDSC2 6.7277 9.2513 3.4572 1.3379
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
QGP-1 GDSC2 0.2596 4.661 -0.2085 42.2226
CFPAC-1 GDSC2 4.3476 6.5758 3.2163 6.9251
PSN1 GDSC2 4.5065 6.1607 3.5515 4.3674
DAN-G GDSC2 4.8119 8.5021 2.6248 9.3688
SUIT-2 GDSC2 4.9356 6.7995 3.5497 3.3668
PaTu 8902 GDSC2 5.0165 6.9073 3.5522 3.1857
YAPC GDSC2 5.0661 6.6301 3.7133 2.1514
Panc 02.03 GDSC2 5.1575 11.014 1.6442 14.214
Panc 08.13 GDSC2 5.2193 8.7561 2.8009 7.2946
SU.86.86 GDSC2 5.2851 7.2381 3.5669 2.5994
HuP-T4 GDSC2 5.3213 7.6396 3.4035 3.4701
Capan-2 GDSC2 5.3966 11.2025 1.731 13.1291
KP-2 GDSC2 5.4624 7.3583 3.6159 2.0467
PaTu 8988t GDSC2 5.5008 12.4207 1.2082 15.6361
HuP-T3 GDSC2 5.5403 10.0149 2.4158 8.8692
KP-4 GDSC2 5.635 9.1555 2.8923 5.8561
Panc 10.05 GDSC2 5.8376 11.095 2.1002 10.0258
PL4 GDSC2 5.9457 7.7542 3.6961 1.0754
MIA PaCa-2 GDSC2 6.0282 7.879 3.6842 1.0475
HPAF-II GDSC2 6.0439 8.0897 3.6061 1.3651
KP-3 GDSC2 6.1684 8.9359 3.3113 2.6242
AsPC-1 GDSC2 6.4344 8.7605 3.5185 1.3541
Capan-1 GDSC2 6.4662 8.0545 3.8025 0.3642
HPAC GDSC2 6.8546 8.6027 3.7541 0.3242
BxPC-3 GDSC2 6.9062 8.9637 3.6437 0.5767
KP-1N GDSC2 7.4754 9.5163 3.6627 0.3075
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H GDSC2 4.5198 7.299 2.9949 7.8402
MPP 89 GDSC2 5.0746 7.452 3.331 4.3933
NCI-H2052 GDSC2 5.62 9.3083 2.8099 6.3712
IST-Mes1 GDSC2 6.1813 9.0068 3.2874 2.728
NCI-H28 GDSC2 6.8462 8.8244 3.671 0.5314
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC GDSC2 4.0763 5.8342 3.3525 6.8915
PC-3 GDSC2 4.9194 11.0783 1.4278 16.0169
VCaP GDSC2 4.9478 6.7658 3.574 3.1952
DU145 GDSC2 6.942 8.8027 3.716 0.3766
22Rv1 GDSC2 7.1646 9.7188 3.4669 0.9696
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC2 5.564 7.8347 3.4609 2.7254
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
UACC-62 GDSC2 -1.2956 1.7289 -1.3413 56.029
SK-MEL-2 GDSC2 2.6811 9.7384 0.1487 29.2868
RPMI-7951 GDSC2 3.0635 7.6851 1.5035 21.5416
WT2-iPS GDSC2 3.2698 7.1527 1.9564 18.2318
M14 GDSC2 4.2163 5.6991 3.5435 5.2447
IGR-37 GDSC2 4.2215 5.6429 3.576 5.0228
SK-MEL-24 GDSC2 4.3232 6.0951 3.4364 5.6028
A-375 GDSC2 4.5531 6.216 3.56 4.1928
WM115 GDSC2 4.607 6.6269 3.3975 5.0745
HT-144 GDSC2 4.6837 9.5919 1.982 13.5772
A101D GDSC2 4.7415 8.264 2.6887 9.1584
A2058 GDSC2 4.7713 6.5255 3.5685 3.6118
GAK GDSC2 4.8487 7.1671 3.3109 5.0222
HMV-II GDSC2 4.9289 8.1082 2.9077 7.3269
G-361 GDSC2 5.0323 7.3886 3.3327 4.474
COLO 679 GDSC2 5.1561 6.9099 3.6394 2.4137
WM35 GDSC2 5.178 11.7576 1.2912 16.0404
WM278 GDSC2 5.2791 7.5701 3.4094 3.5153
Mel JuSo GDSC2 5.5861 10.1352 2.3895 8.9206
WM793 GDSC2 5.6351 7.1672 3.7875 0.9908
COLO 829 GDSC2 5.6543 9.8421 2.5778 7.6667
IGR-1 GDSC2 5.7122 7.39 3.7332 1.1499
CHL-1 GDSC2 5.7944 9.8341 2.6753 6.8047
LOX-IMVI GDSC2 6.0329 8.1468 3.5771 1.5067
CP66-MEL GDSC2 6.0743 7.1539 3.9745 0.1374
SK-MEL-5 GDSC2 6.16 8.6874 3.4138 2.1263
UACC-257 GDSC2 6.2644 7.5706 3.8986 0.2231
G-mel GDSC2 6.3007 7.9543 3.7736 0.526
WM1552C GDSC2 6.3446 7.9946 3.7764 0.4932
SH-4 GDSC2 6.4273 8.414 3.6522 0.8438
COLO 792 GDSC2 7.7446 22.7575 -2.2225 23.4408
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC2 5.2661 7.2798 3.5362 2.807
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
EW-8 GDSC2 0.122 1.6152 0.1192 42.1589
SW982 GDSC2 2.6961 6.0268 1.9059 20.7295
G-402 GDSC2 3.7965 6.1715 2.9296 10.4705
SK-UT-1 GDSC2 4.2465 5.397 3.7203 4.0345
Rh41 GDSC2 4.4558 6.8742 3.1555 7.0038
A-204 GDSC2 4.6132 6.7548 3.3388 5.4272
HT-1080 GDSC2 4.8217 7.6245 3.0664 6.6057
GCT GDSC2 5.0395 14.6242 -0.2441 23.2631
Rh30 GDSC2 5.5197 9.2215 2.7842 6.7327
MES-SA GDSC2 5.819 7.1818 3.8649 0.5333
SW684 GDSC2 5.9841 7.5382 3.7987 0.6465
RKN GDSC2 5.991 7.3111 3.8871 0.3635
VA-ES-BJ GDSC2 6.0984 7.5923 3.8262 0.4828
G-401 GDSC2 6.159 11.8869 1.9393 10.2251
SK-LMS-1 GDSC2 6.1826 9.9989 2.8434 5.1156
KYM-1 GDSC2 6.2165 7.5848 3.8756 0.2913
SW872 GDSC2 6.4183 8.3608 3.6688 0.7918
RD GDSC2 8.0321 16.7477 0.8617 11.9315
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SK-GT-2 GDSC2 0.4876 5.0601 -0.0852 40.4795
AGS GDSC2 4.1684 8.6579 2.0247 14.8295
23132/87 GDSC2 4.1931 5.6392 3.5531 5.2559
NCI-N87 GDSC2 4.3415 8.7367 2.1308 13.6803
SNU-1 GDSC2 4.4261 6.9984 3.0694 7.6303
OCUM-1 GDSC2 4.492 6.9446 3.1495 6.9424
NUGC-3 GDSC2 4.5974 6.1929 3.6049 3.7988
MKN45 GDSC2 4.649 10.445 1.5285 16.2291
MKN1 GDSC2 4.662 8.1311 2.6928 9.3446
RF-48 GDSC2 4.7275 6.6632 3.4697 4.3253
Hs 746.T GDSC2 5.2199 11.4236 1.4889 14.892
SNU-5 GDSC2 5.5432 7.2092 3.7242 1.3858
KATO III GDSC2 5.7376 7.739 3.5991 1.7526
HGC-27 GDSC2 5.999 10.5404 2.4747 7.5501
IM95 GDSC2 6.1156 9.0088 3.2506 3.0109
GCIY GDSC2 6.5538 8.988 3.4825 1.3917
ECC10 GDSC2 6.5624 8.3966 3.7153 0.5535
RERF-GC-1B GDSC2 6.7823 10.4802 2.9708 3.5105
NUGC-4 GDSC2 7.0585 8.9462 3.7088 0.3494
MKN28 GDSC2 7.2426 9.9988 3.3928 1.1701
SNG-M GDSC2 6.5042 8.2336 3.7521 0.4789
⏷ Show the Full List of 21 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IHH-4 GDSC2 3.1128 4.4027 2.9795 12.8402
K5 GDSC2 4.3017 5.7603 3.5858 4.7202
TT2609-C02 GDSC2 4.6313 6.6123 3.4233 4.8513
FTC-133 GDSC2 4.8055 6.583 3.5646 3.5583
B-CPAP GDSC2 5.0231 9.0115 2.5327 9.3948
8305C GDSC2 5.1192 7.4766 3.3494 4.1886
BHT-101 GDSC2 5.2861 7.2383 3.5674 2.5951
WRO GDSC2 5.4475 12.7044 1.0278 16.6705
ASH-3 GDSC2 5.8006 7.4136 3.7657 0.9226
HTC-C3 GDSC2 6.288 9.4391 3.1565 3.2526
CAL-62 GDSC2 6.6354 8.335 3.7665 0.3806
8505C GDSC2 6.6742 8.4896 3.7256 0.4677
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BICR 22 GDSC2 2.5451 4.1815 2.4193 18.4883
SKN-3 GDSC2 4.6012 6.6782 3.3677 5.277
BICR 10 GDSC2 4.811 7.547 3.0966 6.4444
HSC-3 GDSC2 4.8893 12.0785 0.9058 18.7476
SCC-9 GDSC2 5.2257 7.8946 3.2211 4.7374
FaDu GDSC2 5.4002 7.995 3.2874 3.9978
SAS GDSC2 5.464 8.3852 3.145 4.7086
OSC-20 GDSC2 5.5403 8.003 3.3704 3.2679
HSC-4 GDSC2 5.5541 7.4459 3.6279 1.8521
JHU-022 GDSC2 5.5917 10.0798 2.4202 8.728
BB49-HNC GDSC2 5.6746 12.6888 1.2053 15.2202
SCC-15 GDSC2 5.7847 8.0494 3.4898 2.2409
BICR 78 GDSC2 5.8265 8.9848 3.0931 4.3354
DOK GDSC2 5.8596 9.2866 2.974 4.9532
Ca9-22 GDSC2 6.0135 8.4063 3.4576 2.0968
CAL-27 GDSC2 6.1179 7.5116 3.8638 0.3645
SCC-4 GDSC2 6.2572 8.8518 3.394 2.1027
HO-1-N-1 GDSC2 6.2861 8.0394 3.7355 0.6555
NCI-H3118 GDSC2 6.3977 9.1425 3.3428 2.1778
HSC-2 GDSC2 6.6206 7.7386 3.9664 0.0555
LB771-HNC GDSC2 6.6564 8.6686 3.652 0.6915
SAT [Human HNSCC] GDSC2 6.6752 16.2034 0.2099 17.4691
CAL-33 GDSC2 6.7501 12.3418 2.1097 8.1255
PCI-04B GDSC2 6.7639 8.7439 3.6678 0.5826
Detroit 562 GDSC2 6.8265 8.3601 3.8286 0.191
UPCI-SCC-090 GDSC2 6.9221 18.5627 -0.7649 20.646
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KU-19-19 GDSC2 4.5827 6.2681 3.5567 4.1379
RT-112 GDSC2 4.9364 13.2919 0.3382 21.2
5637 GDSC2 4.9519 7.5929 3.1771 5.6078
BFTC-905 GDSC2 5.6726 7.6011 3.6241 1.7123
HT-1197 GDSC2 5.7485 7.979 3.5008 2.2348
SW780 GDSC2 5.8273 7.9982 3.5349 1.9546
639V GDSC2 6.1083 7.2667 3.9477 0.1756
RT-4 GDSC2 6.1329 8.2618 3.5784 1.3947
CAL-29 GDSC2 6.4337 8.1201 3.7658 0.4767
647V GDSC2 6.5873 7.9554 3.8822 0.1622
TCCSUP GDSC2 6.6822 8.3572 3.7765 0.3384
SW1710 GDSC2 6.7253 8.8185 3.6241 0.7378
J82 GDSC2 7.6448 9.6021 3.6938 0.2119
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ME-180 GDSC2 -0.2175 4.0378 -0.5575 46.1886
HEY GDSC2 3.7671 6.0549 2.9587 10.3912
C-33 A GDSC2 4.53 6.4559 3.423 5.1146
PEO1 GDSC2 4.7137 6.8428 3.3712 4.9715
DoTc2 4510 GDSC2 4.8253 7.6293 3.0667 6.5954
Ca Ski GDSC2 4.8961 10.944 1.4764 15.8213
PA-1 GDSC2 5.0627 8.287 2.9177 6.9448
SiHa GDSC2 5.1261 12.6511 0.8071 18.5737
DSH1 GDSC2 5.1577 7.079 3.5621 2.8549
C-4-I GDSC2 5.3827 7.5852 3.4667 2.9966
OVCA420 GDSC2 5.3888 7.3506 3.5772 2.3697
LB831-BLC GDSC2 5.4055 7.3896 3.5693 2.3859
CAL-39 GDSC2 5.4964 7.6748 3.4936 2.655
OVMIU GDSC2 5.6483 11.9096 1.5687 13.3953
BPH-1 GDSC2 5.7844 11.6391 1.7989 11.8266
PWR-1E GDSC2 5.8059 7.7214 3.6416 1.4649
NEC8 GDSC2 5.8413 8.4795 3.3312 2.9935
HT-3 GDSC2 6.0261 8.3005 3.5092 1.8309
HeLa GDSC2 6.0946 15.5351 0.1154 19.1834
MS751 GDSC2 6.2079 10.1165 2.8048 5.2865
SKN GDSC2 6.4858 8.0963 3.795 0.3744
SW756 GDSC2 6.7444 18.0273 -0.6317 20.5617
HEC-1 GDSC2 6.7454 8.3881 3.7892 0.2878
SKG-IIIa GDSC2 6.8665 8.3324 3.8522 0.1461
TC-YIK GDSC2 6.8956 8.4868 3.8097 0.2051
SiSo GDSC2 7.244 15.9926 0.7054 14.1258
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Fludarabine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Fludarabine and Roflumilast. Asthma [CA23] [14]
Ofloxacin DM0VQN3 Minor Decreased absorption of Fludarabine due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [15]
Sparfloxacin DMB4HCT Minor Decreased absorption of Fludarabine due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [15]
Gemifloxacin DMHT34O Minor Decreased absorption of Fludarabine due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [15]
ABT-492 DMJFD2I Minor Decreased absorption of Fludarabine due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [15]
Levofloxacin DMS60RB Minor Decreased absorption of Fludarabine due to intestinal mucosa variation caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [15]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Fludarabine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [16]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Fludarabine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [17]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Fludarabine and Denosumab. Low bone mass disorder [FB83] [18]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Fludarabine and Tecfidera. Multiple sclerosis [8A40] [19]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Fludarabine and Siponimod. Multiple sclerosis [8A40] [20]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Fludarabine and Fingolimod. Multiple sclerosis [8A40] [21]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Fludarabine and Ocrelizumab. Multiple sclerosis [8A40] [22]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Fludarabine and Ozanimod. Multiple sclerosis [8A40] [14]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Fludarabine and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [23]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Fludarabine and Canakinumab. Rheumatoid arthritis [FA20] [24]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Fludarabine and Rilonacept. Rheumatoid arthritis [FA20] [24]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Fludarabine and Golimumab. Rheumatoid arthritis [FA20] [25]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Fludarabine when combined with Anthrax vaccine. Sepsis [1G40-1G41] [26]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Fludarabine and Valganciclovir. Virus infection [1A24-1D9Z] [20]
⏷ Show the Full List of 20 DDI Information of This Drug

References

1 Fludarabine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4802).
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.
7 MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood. 2006 May 15;107(10):4109-14. doi: 10.1182/blood-2005-08-3273. Epub 2006 Jan 26.
8 Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide. PLoS One. 2014 Jun 23;9(6):e99993. doi: 10.1371/journal.pone.0099993. eCollection 2014.
9 Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. Blood. 2001 Nov 1;98(9):2800-7. doi: 10.1182/blood.v98.9.2800.
10 Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. J Cell Biochem. 2008 May 15;104(2):595-605. doi: 10.1002/jcb.21649.
11 Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2006 May 15;107(10):4122-9. doi: 10.1182/blood-2005-11-4465. Epub 2006 Jan 26.
12 Comparative effects of retinoic acid, vitamin D and resveratrol alone and in combination with adenosine analogues on methylation and expression of phosphatase and tensin homologue tumour suppressor gene in breast cancer cells. Br J Nutr. 2012 Mar;107(6):781-90. doi: 10.1017/S0007114511003631. Epub 2011 Aug 1.
13 The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res. 2004 Apr 1;64(7):2590-600. doi: 10.1158/0008-5472.can-03-2631.
14 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
15 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
16 Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
17 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
18 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
19 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
20 Cerner Multum, Inc. "Australian Product Information.".
21 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
22 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
23 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
24 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
25 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
26 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]